Shared on 05 Nov 25
FPH: Fair Value Assessment Will Remain Steady With Minor Discount Rate Adjustment
Analysts have marginally increased their price target for Fisher & Paykel Healthcare to $36.61. This reflects minor adjustments in company fundamentals and updated discount rate assumptions.
Shared on 22 Oct 25
Analysts Hold Price Target for Fisher and Paykel Healthcare as Valuation Inputs Remain Stable
Analysts have maintained their price target for Fisher & Paykel Healthcare at $36.61 per share, citing stable forecasts for discount rate, revenue growth, profit margin, and forward price-to-earnings ratios. Minimal changes were observed in the underlying model inputs.
Shared on 08 Oct 25
Fair value Increased 1.50%Aging Demographics And Product Upgrades Will Expand Respiratory Care
Analysts have modestly increased their price target for Fisher & Paykel Healthcare from $36.06 to $36.61 NZD, reflecting updated forecasts for slightly higher revenue growth and improved profitability expectations. Valuation Changes Fair Value Estimate has risen slightly from NZ$36.06 to NZ$36.61 per share.
Shared on 19 Sep 25
Fair value Increased 1.07%Aging Demographics And Product Upgrades Will Expand Respiratory Care
Fisher & Paykel Healthcare's consensus revenue growth and future P/E forecasts both saw only marginal improvements, underpinning the slight increase in the analyst price target from NZ$35.68 to NZ$36.06. What's in the News Fisher & Paykel Healthcare announced an ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 4, 2025.